DashboardAll companies
Run this on your own research
Healthcare · Biotechnology

Moderna Inc.

MRNANASDAQ$200.10−$2.53 (−1.25%)Market closed

Price Chart

Daily

Key facts

Market Cap
$79.64B
P/E
−27.6x
P/B
9.00x
ROE
−28.9%

Moderna Inc.

Healthcare · Biotechnology · FY 2025

Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.

CEO
Mr. Stéphane Bancel
Employees
5,800

Company Statistics

Valuation

P/E
−27.6x
P/B
9.00x
P/S
40.50x
EV/EBITDA
−30.2x
P/FCF
−37.5x

Margins

Gross
54.8%
EBITDA
−132.0%
Operating
−159.9%
Pre-Tax
−144.0%
Net
−146.8%

Returns

ROA
−21.3%
ROE
−28.9%
ROIC
−20.8%

Growth (CAGR)

Rev 3Yr
−53.3%
Rev 5Yr
47.6%
Op Inc 3Yr
—
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
$2.60B
Net Debt
$1.09B
Debt/Equity
42.6%
Interest Cov
—

Profile

Revenue
$1.92B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Moderna Inc. (MRNA) Stock Forecast 2026 $200.10 — Price, Financials & Analyst Targets | AlphaLenz